Nuveen Asset Management’s Karyopharm Therapeutics KPTI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-32,824
| Closed | -$743K | – | 3379 |
|
|
2024
Q1 | $743K | Buy |
32,824
+2,537
| +8% | +$57.5K | ﹤0.01% | 2824 |
|
|
2023
Q4 | $393K | Buy |
30,287
+127
| +0.4% | +$1.65K | ﹤0.01% | 3080 |
|
|
2023
Q3 | $606K | Sell |
30,160
-742
| -2% | -$14.9K | ﹤0.01% | 2779 |
|
|
2023
Q2 | $830K | Sell |
30,902
-87,667
| -74% | -$2.35M | ﹤0.01% | 2725 |
|
|
2023
Q1 | $6.92M | Buy |
118,569
+12,322
| +12% | +$719K | ﹤0.01% | 1703 |
|
|
2022
Q4 | $5.42M | Sell |
106,247
-25,156
| -19% | -$1.28M | ﹤0.01% | 1863 |
|
|
2022
Q3 | $10.8M | Buy |
131,403
+5,044
| +4% | +$413K | ﹤0.01% | 1430 |
|
|
2022
Q2 | $8.55M | Buy |
126,359
+5,089
| +4% | +$344K | ﹤0.01% | 1616 |
|
|
2022
Q1 | $11.9M | Buy |
121,270
+42,316
| +54% | +$4.16M | ﹤0.01% | 1540 |
|
|
2021
Q4 | $6.72M | Buy |
78,954
+4,353
| +6% | +$370K | ﹤0.01% | 1933 |
|
|
2021
Q3 | $6.79M | Sell |
74,601
-1,127
| -1% | -$103K | ﹤0.01% | 2050 |
|
|
2021
Q2 | $11.7M | Buy |
75,728
+13,757
| +22% | +$2.13M | ﹤0.01% | 1764 |
|
|
2021
Q1 | $9.78M | Sell |
61,971
-6,535
| -10% | -$1.03M | ﹤0.01% | 1816 |
|
|
2020
Q4 | $15.9M | Sell |
68,506
-1,643
| -2% | -$382K | 0.01% | 1393 |
|
|
2020
Q3 | $15.4M | Buy |
70,149
+41,966
| +149% | +$9.19M | 0.01% | 1225 |
|
|
2020
Q2 | $8.01M | Buy |
28,183
+9,235
| +49% | +$2.62M | ﹤0.01% | 1637 |
|
|
2020
Q1 | $5.46M | Sell |
18,948
-11,875
| -39% | -$3.42M | ﹤0.01% | 1664 |
|
|
2019
Q4 | $8.86M | Buy |
30,823
+4,255
| +16% | +$1.22M | ﹤0.01% | 1657 |
|
|
2019
Q3 | $3.83M | Buy |
26,568
+854
| +3% | +$123K | ﹤0.01% | 2102 |
|
|
2019
Q2 | $2.31M | Buy |
+25,714
| New | +$2.31M | ﹤0.01% | 2369 |
|
|
2014
Q3 | – | Sell |
-725
| Closed | -$506K | – | 1536 |
|
|
2014
Q2 | $506K | Buy |
725
+30
| +4% | +$20.9K | ﹤0.01% | 1313 |
|
|
2014
Q1 | $322K | Sell |
695
-542
| -44% | -$251K | ﹤0.01% | 1364 |
|
|
2013
Q4 | $425K | Buy |
+1,237
| New | +$425K | ﹤0.01% | 1279 |
|